MRC Investigators and Directors Directory of Research Programmes at MRC Institutes and Units Foreword

Total Page:16

File Type:pdf, Size:1020Kb

MRC Investigators and Directors Directory of Research Programmes at MRC Institutes and Units Foreword SUMMER 2021 MRC Investigators and Directors Directory of research programmes at MRC Institutes and Units Foreword I am delighted to introduce you to the exceptional To support the MRC Investigators and Directors researchers at our MRC Institutes and Units – the in advancing medical research, MRC provides MRC Investigators and their Directors. core funding to the MRC Institutes and University Units where they carry out their work. These In November 2020, MRC established the new title establishments cover a huge breadth of medical of “MRC Investigator” for Programme Leaders (PL) research from molecular biology to public health. and Programme Leader Track (PLT) researchers at As you will see from the directory, the MRC MRC Institutes and Units. These individuals are Investigators and Directors are making considerable world-class scientists who are either strong leaders advances in their respective fields through their in their field already (PLs) or are making great innovative and exciting research programmes. Their strides towards that goal (PLTs). Based on what accomplishments have been recognised beyond they have achieved in their research careers so far, MRC and many have been awarded notable prizes the title will no doubt become synonymous with and elected to learned societies and organisations. scientific accomplishment, impact and integrity. As well as being widely recognised within the MRC endeavours to do everything it can to support scientific and academic communities, the well- its researchers at all career stages. For this reason, established and newer title of “Director” and we chose not to distinguish between levels of “MRC Investigator”, respectively, are a signal seniority within the new title. We believe this will be to the public of the expert-level status of these an advantage to junior leaders on the Programme individuals. The values and mission of MRC include Leader Track. Having been in their position earlier in disseminating knowledge and promoting dialogue my career, I appreciate the need for a researcher’s with the public about medical research and their CV to stand out amongst the numerous applications affiliation with MRC should bestow confidence and that funders and employers receive. trust in the information our MRC Investigators and Directors provide. The MRC Institute and Unit Directors are outstanding and experienced scientists. As well as I hope that all who read and use this directory leading their own research programmes, they also will enjoy finding out about the brilliant researchers ensure that their Institute or Unit it is achieving we fund at our MRC Institutes and Units. I encourage its mission by recruiting and developing excellent you to connect with them to collaborate and researchers with specialist and transferable skills discover more. that can be applied to carrying out ground-breaking medical research at their establishment. Professor Fiona Watt Executive Chair of the Medical Research Council MRC Units and Institutes The MRC has a mission to support research and Institutes training with the aim of maintaining and improving human health. To address important scientific Institutes adopt broad multidisciplinary opportunities and health needs, we support mission- approaches to address major challenges in focused Institutes*, Units and Centres. These health-related research often requiring ground establishments carry out ground-breaking research breaking methodology and including innovative methodology and technology technology development. development. They are provided with sustained support and Institutes – very long-term flexible multidisciplinary state-of-the-art facilities over a long period of investments time. This allows the use of highly innovative and risky approaches across a flexible range Units – more focused investments established for of disciplines, that would not be feasible in a as long as needed to support a scientific need and/ university setting, to tackle crucially important or deliver a research vision and complex issues over long periods of time. Both are mission-focused and carry out ground- Institutes attract and develop outstanding breaking research including innovative methodology students and early career scientists from the UK, and technology development. Developing and internationally, providing in-depth, advanced strategically driven initiatives, led by an expert research training and a broad multidisciplinary scientific Director, can help promote novel, high risk research environment. approaches, cooperative research programmes, or the development of shared infrastructure. Units Units are set up to meet specific needs, for They are all expected to recruit and, in partnership example, to provide scientific leadership in key with the HEIs and other organisations, develop research fields, or to tackle important research outstanding researchers with specialist and questions where the need cannot easily be transferable skills for academic research, the health addressed through grant funding. This can be services and the national economy. They work in because the research area calls for: partnerships to ensure maximal knowledge transfer for health benefit. Strong and distinctive scientific leadership Close coordination across disciplines In any field, the need for these support mechanisms and activities will change over time. Successful research progress may mean that approaches are quickly integrated Development of methods and technologies into HEI research in the area, or that a unit or centre Support for the development of novel or higher has to change its form and direction. risk programmes and capabilities. Units attract and develop outstanding students and early career programme leaders from the UK and internationally and often have a major impact through developing future research *This booklet features researchers from our Institutes that are solely funded by MRC and does not include leaders in their specialist areas. our partnership Institutes: Health Data Research UK, The Francis Crick Institute and UK Dementia Research Institute. These are major MRC investments and strategic partnerships but as independent organisations that are co-funded by other funding bodies, with their own identity and branding, the MRC Investigator title is not applicable. Contents MRC Laboratory of Molecular Biology Cell Biology Division Dr Buzz Baum 12 Dr Simon Bullock 12 Dr Emmanuel Derivery 13 Dr Ramanujan Hegde 13 Dr Madeline Lancaster 14 Dr Kate McDole 14 Dr Elizabeth Miller 15 Dr Sean Munro 15 Dr John Stuart O’Neill 16 Dr Katja Röper 16 Dr Marta Shahbazi Alonso 17 Neurobiology Division Dr Alexandru Radu Aricescu 17 Dr Anne Bertolotti 18 Dr Albert Cardona 18 Dr Benjamin Falcon 19 Dr Michel Goedert 19 Dr Ingo Greger 20 Dr Michael Hastings 20 Dr Gregory Jefferis 21 Dr Harvey McMahon 21 Dr Jing Ren 22 Dr William Schafer 22 Dr Rebecca Taylor 23 Dr Marco Tripodi 23 Dr Marta Zlatic 24 Protein and Nucleic Acid Chemistry Division Dr Mariann Bienz 24 Dr Gerard Crossan 25 Dr Philipp Holliger 25 Dr Leo James 26 Dr Patrycja Kozik 26 Dr Andrew McKenzie 27 Dr Felix Randow 27 Dr Julian Sale 28 Dr John Sutherland 28 Dr Ana Tufegdzic Vidakovic 29 Dr Roger Williams 29 Dr Joseph Yeeles 30 MRC Laboratory of Molecular Biology cont Structural Studies Division Professor David Barford 30 Dr John Briggs 31 Dr Andrew Carter 31 Professor Julian Gough 32 Dr Richard Henderson 32 Dr Jan Löwe (Director) 33 Dr Garib Murshudov 33 Dr Kelly Nguyen 34 Dr Lori Passmore 34 Dr Venki Ramakrishnan 35 Dr Christopher Russo 35 Dr Sjors Scheres 36 Dr Chris Tate 36 MRC London Institute of Medical Sciences Epigenetics Section Professor Luis Aragón 37 Dr Alexis Barr 37 Professor Dame Amanda Fisher 38 Professor Jesús Gil 38 Professor Petra Hajkova (Interim Director) 39 Dr Harry Leitch 39 Professor Boris Lenhard 40 Dr Enrique Martinez-Perez 40 Professor Matthias Merkenschlager 41 Dr Michelle Percharde 41 Professor David Rueda 42 Dr Peter Sarkies 42 Dr Karen Sarkisyan 43 Dr Mikhail Spivakov 43 Professor Juan Vaquerizas 44 Dr Tobias Warnecke 44 Genes and Metabolism Section Dr André Brown 45 Dr Filipe Cabreiro 45 Professor David Carling 46 Dr Helena Cochemé 46 Professor Stuart Cook 47 Dr Louise Fets 47 Dr Susumu Hirabayashi 48 Professor Irene Miguel-Aliaga 48 Professor Declan O’Regan 49 Dr Chris Schiering 49 Dr Santiago Vernia 50 Dr James Ware 50 Professor Dominic Withers 51 MRC Biostatistics Unit Dr Jessica Barrett 52 Dr Stephen Burgess 52 Professor Daniela De Angelis 53 Professor Thomas Jaki 53 Dr Paul Kirk 54 Professor Sylvia Richardson (Director) 54 Dr Oscar Rueda 55 Dr Brian Tom 55 Dr Sofia Villar 56 Dr Chris Wallace 56 MRC Brain Network Dynamics Unit Professor Rafal Bogacz 57 Professor Timothy Denison 57 Professor David Dupret 58 Professor Peter Magill (Interim Director) 58 Dr Andrew Sharott 59 Professor Huiling Tan 59 MRC Clinical Trials Unit at UCL Professor James Carpenter 60 Dr Angela Crook 60 Professor Diana Gibb 61 Professor Ruth Langley 61 Professor Max Parmar (Director) 62 Professor Sarah Pett 62 Professor Matthew Sydes 63 Professor Jayne Tierney 63 Professor Ann Sarah Walker 64 Professor Ian White 64 MRC Cognition and Brain Sciences Unit Professor Michael Anderson 65 Dr Duncan Astle 65 Dr Kate Baker 66 Dr Robert Carlyon 66 Dr Tim Dalgleish 67 Dr Matt Davis 67 Professor John Duncan 68 Professor Richard Henson 68 Professor Matthew Lambon-Ralph (Director) 69 Dr Tom Manly 69 Dr Dennis Norris 70 Professor James Rowe 70 Dr Alexandra Woolgar 71 MRC Epidemiology Unit Dr Jean Adams 72 Dr Soren Brage 72
Recommended publications
  • ANNUAL REVIEW 1 October 2005–30 September
    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
    [Show full text]
  • Mothers in Science
    The aim of this book is to illustrate, graphically, that it is perfectly possible to combine a successful and fulfilling career in research science with motherhood, and that there are no rules about how to do this. On each page you will find a timeline showing on one side, the career path of a research group leader in academic science, and on the other side, important events in her family life. Each contributor has also provided a brief text about their research and about how they have combined their career and family commitments. This project was funded by a Rosalind Franklin Award from the Royal Society 1 Foreword It is well known that women are under-represented in careers in These rules are part of a much wider mythology among scientists of science. In academia, considerable attention has been focused on the both genders at the PhD and post-doctoral stages in their careers. paucity of women at lecturer level, and the even more lamentable The myths bubble up from the combination of two aspects of the state of affairs at more senior levels. The academic career path has academic science environment. First, a quick look at the numbers a long apprenticeship. Typically there is an undergraduate degree, immediately shows that there are far fewer lectureship positions followed by a PhD, then some post-doctoral research contracts and than qualified candidates to fill them. Second, the mentors of early research fellowships, and then finally a more stable lectureship or career researchers are academic scientists who have successfully permanent research leader position, with promotion on up the made the transition to lectureships and beyond.
    [Show full text]
  • Female Fellows of the Royal Society
    Female Fellows of the Royal Society Professor Jan Anderson FRS [1996] Professor Ruth Lynden-Bell FRS [2006] Professor Judith Armitage FRS [2013] Dr Mary Lyon FRS [1973] Professor Frances Ashcroft FMedSci FRS [1999] Professor Georgina Mace CBE FRS [2002] Professor Gillian Bates FMedSci FRS [2007] Professor Trudy Mackay FRS [2006] Professor Jean Beggs CBE FRS [1998] Professor Enid MacRobbie FRS [1991] Dame Jocelyn Bell Burnell DBE FRS [2003] Dr Philippa Marrack FMedSci FRS [1997] Dame Valerie Beral DBE FMedSci FRS [2006] Professor Dusa McDuff FRS [1994] Dr Mariann Bienz FMedSci FRS [2003] Professor Angela McLean FRS [2009] Professor Elizabeth Blackburn AC FRS [1992] Professor Anne Mills FMedSci FRS [2013] Professor Andrea Brand FMedSci FRS [2010] Professor Brenda Milner CC FRS [1979] Professor Eleanor Burbidge FRS [1964] Dr Anne O'Garra FMedSci FRS [2008] Professor Eleanor Campbell FRS [2010] Dame Bridget Ogilvie AC DBE FMedSci FRS [2003] Professor Doreen Cantrell FMedSci FRS [2011] Baroness Onora O'Neill * CBE FBA FMedSci FRS [2007] Professor Lorna Casselton CBE FRS [1999] Dame Linda Partridge DBE FMedSci FRS [1996] Professor Deborah Charlesworth FRS [2005] Dr Barbara Pearse FRS [1988] Professor Jennifer Clack FRS [2009] Professor Fiona Powrie FRS [2011] Professor Nicola Clayton FRS [2010] Professor Susan Rees FRS [2002] Professor Suzanne Cory AC FRS [1992] Professor Daniela Rhodes FRS [2007] Dame Kay Davies DBE FMedSci FRS [2003] Professor Elizabeth Robertson FRS [2003] Professor Caroline Dean OBE FRS [2004] Dame Carol Robinson DBE FMedSci
    [Show full text]
  • EMBC Annual Report 2007
    EMBO | EMBC annual report 2007 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION | EUROPEAN MOLECULAR BIOLOGY CONFERENCE EMBO | EMBC table of contents introduction preface by Hermann Bujard, EMBO 4 preface by Tim Hunt and Christiane Nüsslein-Volhard, EMBO Council 6 preface by Marja Makarow and Isabella Beretta, EMBC 7 past & present timeline 10 brief history 11 EMBO | EMBC | EMBL aims 12 EMBO actions 2007 15 EMBC actions 2007 17 EMBO & EMBC programmes and activities fellowship programme 20 courses & workshops programme 21 young investigator programme 22 installation grants 23 science & society programme 24 electronic information programme 25 EMBO activities The EMBO Journal 28 EMBO reports 29 Molecular Systems Biology 30 journal subject categories 31 national science reviews 32 women in science 33 gold medal 34 award for communication in the life sciences 35 plenary lectures 36 communications 37 European Life Sciences Forum (ELSF) 38 ➔ 2 table of contents appendix EMBC delegates and advisers 42 EMBC scale of contributions 49 EMBO council members 2007 50 EMBO committee members & auditors 2007 51 EMBO council members 2008 52 EMBO committee members & auditors 2008 53 EMBO members elected in 2007 54 advisory editorial boards & senior editors 2007 64 long-term fellowship awards 2007 66 long-term fellowships: statistics 82 long-term fellowships 2007: geographical distribution 84 short-term fellowship awards 2007 86 short-term fellowships: statistics 104 short-term fellowships 2007: geographical distribution 106 young investigators 2007 108 installation
    [Show full text]
  • Lyon Playfair: Chemist and Commissioner, 1818–1858
    Science Museum Group Journal Lyon Playfair: chemist and commissioner, 1818–1858 Journal ISSN number: 2054-5770 This article was written by Ian Blatchford 05-04-2021 Cite as 10.15180; 211504 Research Lyon Playfair: chemist and commissioner, 1818–1858 Published in Spring 2021, Issue 15 Article DOI: http://dx.doi.org/10.15180/211504 Abstract Lyon Playfair was a multi-talented man: a scientist, administrator and politician whose life and influence deserve further research. This article concentrates on the period between 1818 and 1858, from Playfair’s birth to his appointment as Professor of Chemistry at the University of Edinburgh. His biographer (Sir Thomas Wemyss Reid) described his life as a ‘story not of adventure, but work’ and yet his record was one of energetic enterprise that had considerable impact. He was a rising star in the then fashionable world of chemistry, a favoured student of the founder of organic chemistry, Justus Liebig, and a central figure in the promotion of new ideas in agricultural science.[1] A career in science and the state saw him connected to the leading figures of both, and he played a crucial role in the conceptual and financial success of the Great Exhibition, and its legacy. His brilliance has been overshadowed by the extrovert Henry Cole, and yet Playfair was essential to the major educational reforms of their time. Component DOI: http://dx.doi.org/10.15180/211504/001 Keywords Lyon Playfair, chemistry, politics, biography, University of Edinburgh, Justus Liebig, Great Exhibition Introduction [2] Playfair was a versatile man: scientist, administrator and politician. This article concentrates on the period between 1818 and 1858, from his birth to his appointment as Professor of Chemistry at Edinburgh.
    [Show full text]
  • Science & Policy Meeting Jennifer Lippincott-Schwartz Science in The
    SUMMER 2014 ISSUE 27 encounters page 9 Science in the desert EMBO | EMBL Anniversary Science & Policy Meeting pageS 2 – 3 ANNIVERSARY TH page 8 Interview Jennifer E M B O 50 Lippincott-Schwartz H ©NI Membership expansion EMBO News New funding for senior postdoctoral In perspective Georgina Ferry’s enlarges its membership into evolution, researchers. EMBO Advanced Fellowships book tells the story of the growth and ecology and neurosciences on the offer an additional two years of financial expansion of EMBO since 1964. occasion of its 50th anniversary. support to former and current EMBO Fellows. PAGES 4 – 6 PAGE 11 PAGES 16 www.embo.org HIGHLIGHTS FROM THE EMBO|EMBL ANNIVERSARY SCIENCE AND POLICY MEETING transmissible cancer: the Tasmanian devil facial Science meets policy and politics tumour disease and the canine transmissible venereal tumour. After a ceremony to unveil the 2014 marks the 50th anniversary of EMBO, the 45th anniversary of the ScienceTree (see box), an oak tree planted in soil European Molecular Biology Conference (EMBC), the organization of obtained from countries throughout the European member states who fund EMBO, and the 40th anniversary of the European Union to symbolize the importance of European integration, representatives from the govern- Molecular Biology Laboratory (EMBL). EMBO, EMBC, and EMBL recently ments of France, Luxembourg, Malta, Spain combined their efforts to put together a joint event at the EMBL Advanced and Switzerland took part in a panel discussion Training Centre in Heidelberg, Germany, on 2 and 3 July 2014. The moderated by Marja Makarow, Vice President for Research of the Academy of Finland.
    [Show full text]
  • Wellcome Investigators March 2011
    Wellcome Trust Investigator Awards Feedback from Expert Review Group members 28 March 2011 1 Roughly 7 months between application and final outcome The Expert Review Groups 1. Cell and Developmental Biology 2. Cellular and Molecular Neuroscience (Zaf Bashir) 3. Cognitive Neuroscience and Mental Health 4. Genetics, Genomics and Population Research (George Davey Smith) 5. Immune Systems in Health and Disease (David Wraith) 6. Molecular Basis of Cell Function 7. Pathogen Biology and Disease Transmission 8. Physiology in Health and Disease (Paul Martin) 9. Population and Public Health (Rona Campbell) 2 Summary Feedback from ERG Panels • The bar is very high across all nine panels • Track record led - CV must demonstrate a substantial impact of your research (e.g. high impact journals, record of ground breaking research, clear upward trajectory etc) To paraphrase Walport ‘to support scientists with the best track records, obviously appropriate to the stage in their career’ • Notable esteem factors (but note ‘several FRSs were not shortlisted’) • Your novelty of your research vision is CRUCIAL. Don’t just carry on doing more of the same • The Trust is not averse to risk (but what about ERG panel members?) • Success rate for short-listing for interview is ~15-25% at Senior Investigator level (3-5 proposals shortlisted from each ERG) • Fewer New Investigator than Senior Investigator applications – an opportunity? • There are fewer applications overall for the second round, but ‘the bar will not be lowered’ The Challenge UoB has roughly 45 existing
    [Show full text]
  • Honorary Degrees 2011
    Honorary Degrees 2011 The full list of those who received honorary degrees is as follows: COMMEMORATION DAY, WEDNESDAY 15 JUNE 2011 DEGREE OF DOCTOR OF DIVINITY (DD) Very Reverend David LUNAN, Clerk to the Presbytery of Glasgow DEGREE OF DOCTOR OF LAWS (LLD) Baroness Brenda HALE, Barrister and Judge DEGREE OF DOCTOR OF LETTERS (DLitt) Professor Toshiyuki TAKAMIYA, Emeritus Professor, Keio University, Tokyo DEGREE OF DOCTOR OF SCIENCE (DSc) Professor Sir Leszek BORYSIEWICZ, Vice-Chancellor of the University of Cambridge & former Chief Executive of the MRC Professor Victor J DZAU, James B Duke Professor of Medicine, Duke University, USA DEGREE OF DOCTOR OF THE UNIVERSITY (DUniv) Lord John MCFALL of Alcuith, Former MP for West Dunbartonshire SUMMER GRADUATIONS DEGREE OF DOCTOR OF LETTERS (DLitt) 5 March FAN ZENG, Prominent Artist in traditional Chinese Art DEGREE OF DOCTOR OF LETTERS (DLitt) GSA Graduation 17 June Katrina BROWN, Director of the Glasgow International Festival of Visual Arts DEGREE OF DOCTOR OF LETTERS (DLitt) 23 June 11am Professor Simon BLACKBURN, Faculty of Philosophy, University of Cambridge DEGREE OF DOCTOR OF LETTERS (DLitt) 28 June 11am Professor Sir Hilary BECKLES, University of West Indies, West Indies Professor Caroline Walker BYNUM, Emeritus Professor, Columbia University, USA DEGREE OF DOCTOR OF LETTERS (DLitt) 28 June 4pm Armando IANNUCCI, Comedy Writer, Producer and Director DEGREE OF DOCTOR OF LETTERS (DLitt) 6 July Crichton Campus Alastair REID, Writer and Translator DEGREE OF DOCTOR OF SCIENCE (DSc) 10 February
    [Show full text]
  • EMBO Conference Takes to the Sea Life Sciences in Portugal
    SUMMER 2013 ISSUE 24 encounters page 3 page 7 Life sciences in Portugal The limits of privacy page 8 EMBO Conference takes to the sea EDITORIAL Maria Leptin, Director of EMBO, INTERVIEW EMBO Associate Member Tom SPOTLIGHT Read about how the EMBO discusses the San Francisco Declaration Cech shares his views on science in Europe and Courses & Workshops Programme funds on Research Assessment and some of the describes some recent productive collisions. meetings for life scientists in Europe. concerns about Journal Impact Factors. PAGE 2 PAGE 5 PAGE 9 www.embo.org COMMENTARY INSIDE SCIENTIFIC PUBLISHING panels have to evaluate more than a hundred The San Francisco Declaration on applicants to establish a short list for in-depth assessment, they cannot be expected to form their views by reading the original publications Research Assessment of all of the applicants. I believe that the quality of the journal in More than 7000 scientists and 250 science organizations have by now put which research is published can, in principle, their names to a joint statement called the San Francisco Declaration on be used for assessment because it reflects how the expert community who is most competent Research Assessment (DORA; am.ascb.org/dora). The declaration calls to judge it views the science. There has always on the world’s scientific community to avoid misusing the Journal Impact been a prestige factor associated with the publi- Factor in evaluating research for funding, hiring, promotion, or institutional cation of papers in certain journals even before the impact factor existed. This prestige is in many effectiveness.
    [Show full text]
  • 'Astrazeneca' Covid-19 Vaccine
    Medicines Law & Policy How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine By Christopher Garrison 1. Introduction. The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media reporting about the vaccine tends to focus either on the very small (non-profit, academic) Jenner Institute at Oxford University, where the vaccine was first invented, or the very large (‘Big Pharma’ firm) AstraZeneca, which is now responsible for organising its (non-profit) world-wide development, manufacture and distribution. However, examining the intellectual property (IP) path of the vaccine from invention to manufacture and distribution reveals a more complex picture that involves other important actors (with for-profit perspectives). Mindful of the very large sums of public money being used to support Covid-19 vaccine development, section 2 of this note will therefore contextualise the respective roles of the Jenner Institute, AstraZeneca and these other actors, so that their share of risk and (potential) reward in the project can be better understood. Section 3 provides comments as well as raising some important questions about what might yet be done better and what lessons can be learned for the future. 2. History of the ‘Oxford / AstraZeneca’ vaccine. 2.1 Oxford University and Oxford University Innovation Ltd. The Bayh-Dole Act (1980) was hugely influential in the United States and elsewhere in encouraging universities to commercially exploit the IP they were generating by setting up ‘technology transfer’ offices.
    [Show full text]
  • A Year in the Life of the Trinity Hall Community Rinity Hall Review 2018/19 2018/19 T Trinity Hall CAMBRIDGE
    TRINITY HALL CAMBRIDGE Trinity Hall Review 2018/19 Academic Year 2018/19 Academic Year Trinity Hall Trinity A year in the Hall life community of the Trinity 2018/19 2018/19 Trinity Hall 2 Reports from It has been a wonderful year in the Alumni and Development Office. We have met our Officers over 800 of you at events in the UK and in 12 cities overseas; launched our online community LinkHall; and awarded the Cambridge Social Innovation Prize to four businesses making a positive social impact in the UK. Judging from the alumni news section of the Review (pages 36-37), it has also been a great year for many of you too. It is always a pleasure to hear how our alumni are and what you’re getting up to, so thank you for sharing your news with us. Your support has been keenly felt in the past year. Thanks to your generosity we have been able to provide financial aid to undergraduates; offer studentships to postgraduates; help cover the costs of the wellbeing team; support access initiatives; and refurbish student facilities. Your support is invaluable to our students and is hugely appreciated across the College. Thank you. Kathryn Martin-Chambers (née Greaves) Alumni Communications Officer Note: You may notice there is no report from Andrew Arthur, Director of Music, in this issue. Andrew was on sabbatical leave in the academic year 2018/19 but has reprised his role for 2019/20. Stay in touch with the College network: 32 Alumni @TrinityHallCamb News inside Reports from our Officers 2 The Master 2 The Bursar 4 The Senior Tutor 7 The Graduate Tutor
    [Show full text]
  • ACCEA Personal Statements
    ACCEA BRONZE AWARD 2016 Name: PAUL AVEYARD GMC/GDC Number: 3332407 Speciality: ACADEMIC GP My research showed for the first time that primary care teams were ineffective at supporting weight loss, but referral to commercial weight management services was effective and cheaper. This research is cited in NICE guidelines and informed Department of Health guidance, leading to a doubling of referral to commercial providers and decline in primary care treatment. I trained GPs to deliver a 30-second intervention to promote these referrals and showed that screening for obesity is popular with patients, easy for GPs to deliver, and led to 2.5kg of weight loss. My research created a new approach to GP brief interventions to motivate smoking cessation. The national online training video has been used by 95,000 clinicians. My subsequent work with the Department of Health changed national guidelines, increasing referrals by 39%. My research showed that smoking reduction creates lasting cessation and influenced NICE guidelines. I was the GP member of the guideline group and launched the guidance at the NICE press conference, making England the first country in the world to implement a harm reduction strategy. I am one of four editors of the Cochrane Tobacco Addiction Group and our reviews are cited four times more than the Cochrane average. Our work is cited in UK and many other countries' national guidelines. ACCEA BRONZE AWARD 2016 Name: TREVOR THOMPSON GMC/GDC Number: 3494806 Speciality: ACADEMIC GP I am an NHS clinician dedicated to creating "Tomorrow's Doctors": 1. In 2015 I was awarded a National Teaching Fellowship by the Higher Education Academy (Google: HEA Trevor Thompson).
    [Show full text]